Work

Borealis-2: A randomized phase II study of OGX-427 (apatorsen) plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial cancer (mUC) (Hoosier Cancer Research Network GU12-160).

Year: 2017

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2017.35.6_suppl.289

Authors: Toni K. Choueiri, Noah M. Hahn, Lillian Werner, Meredith M. Regan, Jonathan E. Rosenberg, BOREALIS-02 investigators

Institutions: Dana-Farber/Harvard Cancer Center, Johns Hopkins University, Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center

Language: English

Topic: Bladder and Urothelial Cancer Treatments

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2603518793

Cites:

Cited by: 8

Related to: 10